SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:mau-3919"
 

Sökning: onr:"swepub:oai:DiVA.org:mau-3919" > In Vivo Investigati...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00002985naa a2200409 4500
001oai:DiVA.org:mau-3919
003SwePub
008200228s2010 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:mau:diva-39192 URI
024a https://doi.org/10.1002/jps.219692 DOI
040 a (SwePub)mau
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Albrecht, Karin4 aut
2451 0a In Vivo Investigation of Thiomer-Polyvinylpyrrolidon Nanoparticles Using Magnetic Resonance Imaging
264 1b Wiley Inter Science,c 2010
338 a print2 rdacarrier
520 a This study focused on the investigation of the permeation enhancing effects of a stomach targeted, nanoparticulate drug delivery system. The polyacrylic acid–cysteine/polyvinylpyrrolidon nanoparticles were loaded with the magnetic resonance imaging (MRI) contrast agent diethylenetriaminepentaacetic acid gadolinium( III)dihydrogen salt (Gd-DTPA). Average particle size was determined to be 130nm and the optimum for stability was found to be below a pH of 4.5. In vitro permeation studies were performed on rat gastric mucosa and revealed an eightfold increase in Gd- DTPA uptake when incorporated in the nanoparticles compared to evaluation in the presence of unformulated polyacrylic acid–cysteine. In vivo investigations with rats were performed via the noninvasive MRI method in order to track the nanoparticles way through the gastrointestinal tract. When Gd-DTPA was administered orally as nanoparticulate suspension, an increased MRI signal in the urinary bladder was detected after 34 min, providing evidence for systemic uptake and renal elimination of the contrast agent. As control experiments with Gd-DTPA only or in combination with unformulated polyacrylic acid–cysteine revealed no MRI signal increase at all, the significant permeation enhancing effect could be identified based on the nanoparticulate formulation.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng
653 a nanoparticles
653 a oral drug delivery
653 a absorption enhancer
653 a polymeric drug delivery
700a Greindl, Melanie4 aut
700a Deutel, Britta4 aut
700a Kremser, Christian4 aut
700a Wolf, Christian4 aut
700a Talasz, Heribert4 aut
700a Stollenwerk, Maria Magdalena,d 1959-4 aut
700a Debbage, Paul4 aut
700a Bernkop-Schnürch, Andreas4 aut
773t Journal of Pharmaceutical Sciencesd : Wiley Inter Scienceg 99:4, s. 2008-2017q 99:4<2008-2017x 0022-3549x 1520-6017
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:mau:diva-3919
8564 8u https://doi.org/10.1002/jps.21969

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy